BOARD OF DIRECTORS

Kristina Burow

Kristina Burow is a Partner with ARCH, joining the firm in 2002. Her investment focus includes biotechnology, pharmaceuticals, alternative energy and chemicals. Ms. Burow is a co-founder and director of Sapphire Energy and a director of Lycera, Receptos and Limerick BioPharmaceuticals. She has participated in the funding and development of several other portfolio companies including Ensemble Discovery, Achaogen, Kythera Biopharmaceuticals, Ikaria, Accelerator Corporation and Quanterix.

Ms. Burow joined ARCH from the Novartis BioVenture Fund in San Diego where she was involved in numerous investments in the life science sector. Previously, as an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development.

Ms. Burow holds an M.B.A. from The University of Chicago, an M.A. in Chemistry from Columbia University, and a B.S. in Chemistry from the University of California, Berkeley.

Mary Campbell, M.B.A., Observer

Mary Campbell is a Managing Director and Founder of EDF Ventures. Mary received her M.B.A. from the University of Michigan; her M.A. in Special Education from Fairfield University; and her B.A. in English from the University of Michigan. She has been an active investor both in healthcare and information technology companies for over 20 years.

Currently, Mary sits on the boards of HandyLab, Health Care Solutions, Rhevision Technology, ValenTx and is a board observers for Cerenis Therapeutics, The Echo Group, and QuadraSpec. In 1997, Mary led the firm’s most successful transaction, Pixelworks, a leader of system-on-a-chip integrated circuits for the advanced display market which went public in 2000 (NASDAQ: PXLW). She has been the lead investor for six of the firm’s investments in healthcare companies and five of its investments in information technology companies.

Mary is active with The Stephen M. Ross School of Business at the University of Michigan and currently serves as an advisor to the Zell Lurie Institute for Entrepreneurial Studies as well as its student-run venture activity, the Wolverine Venture Fund. She is an advisor to the University of Michigan’s Life Science Institute. She is a member of the Steering Committee for the Michigan Strategic Economic Investment and Commercialization Board, a Statewide initiative to foster research and commercialization. Mary is also President of the Michigan Venture Capital Association, the State’s premier public policy advocate for the private equity/venture capital industry.

Gary D. Glick, Ph.D.

Dr. Gary D. Glick founded Lycera Corp. in 2006 and raised the seed round and series A financing for the company. He obtained his Ph.D. from Columbia University in 1988, studying organic chemistry under the direction of W. Clark Still. He then completed a National Institutes of Health postdoctoral fellowship at Harvard University where he studied bio-organic chemistry in the laboratory of Jeremy R. Knowles. In 1990, Dr. Glick joined the chemistry faculty at the University of Michigan in Ann Arbor, where he presently holds the Werner E. Bachmann chair in chemistry, is a professor in the Department of Biological Chemistry at the University of Michigan Medical School, and is a member of the training faculty for the interdepartmental Immunology and Medicinal Chemistry doctoral programs. He is also the founder and director of the Chemical Biology Doctoral Program at Michigan. Dr. Glick’s research interests are in drug discovery and development for autoimmune diseases and cancer; chemical-induced apoptosis; nucleic acid structure, folding and recognition; and molecular recognition of nucleic acids by proteins.

Dr. Glick has served and continues to serve on numerous boards and committees, including the Bioorganic & Natural Products Chemistry Study Section of the National Institutes of Health and the Scientific Advisory Board of the National Arthritis Foundation, Michigan Chapter. He serves on several editorial boards, is Editor-in-Chief of Biopolymers, a leading journal publishing in the areas of biochemistry and biophysics, and is a counselor to the American Chemical Society Division of Biological Chemistry.

Dr. Glick’s scientific contributions have been recognized with a number of different awards including, an Arthritis Investigator Award from the National Arthritis Foundation, a Junior Faculty Research Award from the American Cancer Society, a Young Investigator Award from the National Science Foundation, a Camille Dreyfus Teacher-Scholar Award, a Research Fellowship from the Alfred P. Sloan Foundation, two Research Excellence Awards from the University of Michigan, and is a Fellow of the American Association for the Advancement of Science.

Robert Kamen, Ph.D.

Dr. Kamen is a consultant to the biotech and pharmaceutical industry. His industrial career began with the biotechnology company Genetics Institute, Inc., where he played a leadership role in building the Cambridge, Massachusetts, firm. Appointed to director of research in 1982, Dr. Kamen became vice president for research in 1984 and was promoted in 1986 to senior vice president, scientific affairs. He was responsible for discovery/pre-clinical research activities and established the clinical development department. Wyeth acquired Genetics Institute in 1991.

Most recently, he was president of Abbott Bioresearch Center, Abbott Laboratories’ immunology drug discovery and biologics production unit in Worcester, Massachusetts, and a member of the Abbott Pharmaceuticals Executive Management Committee. During Dr. Kamen’s leadership at BASF/Abbott, the company established the technology platform for Humira™ (adalimumab), the first fully human antibody to achieve marketing approval in the US (and Europe). Currently marketed for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and psoriasis, it was in 2007 and 2008 the most rapidly growing US biological drug.

In 2005 Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, where he serves as chairman. He is also a member of several other biopharmaceutical company boards. Dr. Kamen has an undergraduate degree in biophysics from Amherst College (summa cum laude) and a Ph.D. in biochemistry and molecular biology from Harvard University

Nina Kjellson

Nina Kjellson is a general partner at InterWest Partners, a leading diversified venture capital firm. She focuses primarily on investments in biopharmaceuticals. In addition to serving on the board of Alvine Pharmaceuticals, she is a board member of Eiger Biopharmaceuticals, Lycera, Primera Diagnostics, Sequel and Trius Therapeutics. Kjellson led InterWest’s investment in APT Pharmaceuticals and Nereus Pharmaceuticals where she is an observer on the board. Additionally, she supports InterWest’s investments in AkaRx, Devax, Kanisa, and MacuSight.

Kjellson’s past successfully exited investments include Aspreva Pharmaceuticals (acquired by Galenica) and NovaCardia (acquired by Merck).

Prior to joining InterWest, Kjellson was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Kjellson began her career conducting health policy and survey research with the Kaiser Family Foundation.

Kjellson received a B.S. in human biology from Stanford University.

Jeffrey Leiden, M.D., Ph.D.

Jeffrey Leiden, MD, PhD is a Managing Director at Clarus Ventures, a life sciences venture capital firm with more than $1.2 B under management. He has more than 20 years of experience in the biomedical and pharmaceutical sectors. Dr. Leiden was President and COO of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Abbott Board of Directors and the TAP Board of Directors from 2000-2006. From 1987-2000, Dr. Leiden held several academic appointments including the Rawson Professor and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. During his academic career, Dr. Leiden was involved in starting several biotechnology companies including Vical and Cardiogene. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences.

Dr. Leiden is the Chairman of the Board of Directors of both TyRx Pharma and Variation Biotechnologies Inc.., and a member of the Board of Directors of Biolex Therapeutics. Dr. Leiden is also a non-executive director of Shire plc and a member of the Executive Committee of the Board of Trustees of the Ravinia Festival and a trustee of the University of Pennsylvania School of Medicine. Dr. Leiden received both his MD and PhD degrees from the University of Chicago and an honorary MA from Harvard University.

Tim Mayleben, M.B.A.

Timothy M. Mayleben, is an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors. Prior to this he served as the President and Chief Operating Officer and a Director of NightHawk Radiology Holdings, Inc. Mr. Mayleben was formerly the Chief Operating Officer of Esperion Therapeutics, which later became a division of Pfizer Global Research & Development. He joined Esperion in late 1998 as Chief Financial Officer. While at Esperion, Mr. Mayleben led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in December 2003. Prior to joining Esperion, Mr. Mayleben held various senior and executive management positions at Transom Technologies, Inc., now part of Electronic Data Systems, Inc., and Applied Intelligent Systems, Inc., which was acquired by Electro-Scientific Industries, Inc. in 1997. Mr. Mayleben holds a Masters of Business Administration with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Business Administration degree from the University of Michigan Ross Business School. He is on the Advisory Board for the Wolverine Venture Fund and serves as a director for several public and private life science companies.

William J. Sibold

Bill is an accomplished leader with multi-functional international experience in the pharmaceutical, biotech and associated outsourcing industries. Bill started his career with Eli Lilly Canada in Sales. At Amgen Bill was a Product Manager in Epogen Marketing responsible for developing product strategy, tactical plans, and analytical decision-making.

In addition to his biotech and pharma experience Bill worked for one of the first Site Management Organizations in the country. ICSL operated over 50 clinical trial sites with phase I-IV trial capabilities. There, Bill led the Business Development and Sales departments.

Bill joined Biogen Idec as the Director of New Products Commercialization in 2001 where he was responsible for creating the commercial strategy and aligning stakeholder’s opinions of the early stage pipeline. Next, Bill moved to Sydney to run Biogen Idec’s Australia Asia Pacific business which included Australia, New Zealand, and several Asian countries. Bill returned to the US as the VP of Commercial Operations for the Neurology Strategic Business Unit where he oversaw Sales, Marketing and Patient Services. He relaunched Tysabri under a complicated Risk Minimization Plan mandated by the FDA and achieved significant sales growth milestones. He was promoted to Senior Vice President, US Neurology then Senior Vice President US Commercial where he oversaw Oncology, Rheumatology and Neurology (~800 employees) and a P&L of over $2.5 billion.

Bill has a MBA from Harvard University and a BA in Molecular Biophysics and Biochemistry from Yale University where he also was a member of the varsity tennis team and captain in his senior year.